Evaluation of NWRD09 for Female Participants With Persistent HPV16 Infection

Summary

This is a two-part, phase I/IIa study, intended to evaluate the safety, tolerability, immunogenicity, and efficacy of NWRD09 in female participants with persistent HPV16 infection, and to determine the MTD, and/or RP2D of NWRD09.

Timeline

Start

2026-10

Primary completion

2027-09

Completion

2027-11

Drugs

Indications